Morgan Stanley
CERE

Morgan Stanley’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Morgan Stanley’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-330,728
Closed -$13.5M – 8124
2024
Q2 		$13.5M Sell
330,728
-182,763
-36% -$7.61M ﹤0.01% 3074
2024
Q1 		$21.7M Sell
513,491
-998,413
-66% -$41.9M ﹤0.01% 2607
2023
Q4 		$64.1M Buy
1,511,904
+1,428,265
+1,708% +$41M ﹤0.01% 2189
2023
Q3 		$1.83M Sell
83,639
-77,061
-48% -$1.93M ﹤0.01% 4444
2023
Q2 		$5.11M Sell
160,700
-60,064
-27% -$1.84M ﹤0.01% 3765
2023
Q1 		$5.38M Sell
220,764
-330,713
-60% -$9.71M ﹤0.01% 3727
2022
Q4 		$17.4M Buy
551,477
+50,520
+10% +$1.43M ﹤0.01% 2487
2022
Q3 		$14.2M Buy
500,957
+115,673
+30% +$3.44M ﹤0.01% 2584
2022
Q2 		$10.2M Buy
385,284
+279,674
+265% +$7.94M ﹤0.01% 3047
2022
Q1 		$3.7M Buy
105,610
+62,695
+146% +$1.83M ﹤0.01% 4004
2021
Q4 		$1.39M Buy
42,915
+16,837
+65% +$594K ﹤0.01% 4852
2021
Q3 		$768K Buy
26,078
+10,551
+68% +$296K ﹤0.01% 5226
2021
Q2 		$397K Buy
15,527
+10,227
+193% +$146K ﹤0.01% 5671
2021
Q1 		$73K Sell
5,300
-9,086
-63% -$133K ﹤0.01% 6175
2020
Q4 		$238K Buy
+14,386
New +$187K ﹤0.01% 5505

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Morgan Stanley's CERE Position: Q3 2024 in Review

Morgan Stanley sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 330,728 shares — an estimated $13.5M sold.

Morgan Stanley first reported a position in CERE in Q4 2020 and held it in 15 quarters. The position peaked at $64.1M in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Morgan Stanley reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Morgan Stanley sold 330,728 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $13.5M.
  • Morgan Stanley first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 15 quarters.
  • Morgan Stanley's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $64.1M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Morgan Stanley's 13F filing for Q3 2024, filed 14 Nov 2024.